Dr. Reddy's Loses Bid To Invalidate Teva Patents

Law360, New York (March 5, 2008, 12:00 AM EST) -- A district judge has allowed Teva Pharmaceutical Industries Ltd. to proceed with its lawsuit to bar Dr. Reddy's Laboratories Inc. from marketing a generic version of GlaxoSmithKline Inc.'s congestive heart failure drug Coreg.

Dr. Reddy's had asked the U.S. District Court for the District of New Jersey in October for a partial summary judgment that the first two claims of one of the patents at issue, known as the '008 patent, were invalid because they were anticipated by prior art.

Teva, an Israel-based generic drug company,...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.